Analysis of pathological response rate and influencing factors of neoadjuvant therapy with paclitaxel combined with carboplatin dense regimen for TNBC
Objective To investigate the pathological efficacy of neoadjuvant therapy with paclitaxel combined with carboplatin dense regimen in patients with triple-negative breast cancer(TNBC)and analyze the influencing factors of pathological response rate.Methods A total of 136 patients diagnosed with TNBC in the hospital from January 2022 to December 2023 were selected.All patients received neoadjuvant therapy with paclitaxel combined with carboplatin dense regimen.The breast pathological complete response(bpCR)rates among patients with different clinical characteristics were statistically compared.Logistic regression model was used to analyze the influencing factors of bpCR rate,and drug adverse reactions were observed.Re-sults All 136 patients were evaluable for clinical efficacy,with an overall response rate(ORR)of 89.71％ and a bpCR rate of 49.26％ .There were no statistically significant differences in bpCR rates among patients with different body mass index,menstrual status,and vascular invasion(P＞0.05).However,statistically sig-nificant differences were observed in bpCR rates among patients of different ages,clinical stages,Eastern Co-operative Oncology Group(ECOG)performance status scores,lymph node metastasis,and degrees of differ-entiation(P＜0.05).Logistic regression model analysis showed that clinical stage Ⅲ[odds ratio(OR)=3.438,95％ confidence interval(95％ CI)1.815-6.514]and low-to-moderate degrees of differentiation in tis-sues(OR=2.450,95％ CI 1.191-5.039)were independent risk factors affecting the bpCR rate(P＜0.05).Among the 136 patients,common adverse reactions after neoadjuvant therapy with paclitaxel combined with carboplatin dense regimen were mainly grade Ⅰ-Ⅱ.which did not affect the subsequent treatment of patients after active symptomatic treatment.Conclusion Neoadjuvant therapy with paclitaxel combined with carbopla-tin dense regimen for TNBC patients exhibits good short-term efficacy.Clinical stage Ⅲ and low-to-moderate degrees of differentiation in tissues are independent risk factors affecting the bpCR rate.The adverse reactions are tolerable,and the treatment regimen has good safety.
Triple-negative breast cancerNeoadjuvant therapyPaclitaxelCarboplatinDense regimenPathological response rateInfluencing factors
万方数据
维普
